key: cord-0922593-x9t3x5mo
authors: Ouertani, E.; Nesrine, M.; Berrazega, Y.; Rachdi, H.; Bohli, M.; Kochbati, L.; Boussen, H.
title: 1593P COVID-19 vaccine acceptance among Tunisian cancer patients: A cross-sectional study
date: 2021-09-30
journal: Annals of Oncology
DOI: 10.1016/j.annonc.2021.08.1586
sha: db30da53bea1222a5f8108eb73411eedea3ebb83
doc_id: 922593
cord_uid: x9t3x5mo

nan

the vaccination. Here, we evaluated attitude towards and effects of COVID-19 vaccination in patients with breast or gynecological cancer. The aim was to improve counseling of our patients in clinical routine.

Methods: Since March 15 th 2021, patients who received one of the approved COVID-19 vaccines were routinely interviewed about immediate (0-2 days) and late side effects (within two weeks after vaccination). Clinical parameters such as current therapy, time interval between therapy administration and vaccination, and changes in the therapy schedule due to the vaccination were documented. Furthermore, the willingness of non-vaccinated patients to be vaccinated was assessed. The collected data were anonymously analyzed as a part of routine quality assurance.

Results: By May 10 th 2021, 111 out of 217 (51.1%) interviewed patients had received at least one shot of COVID-19 vaccine and 21 patients both shots. More than half of the vaccinated patients were >55y (60.2%; mean: 60.7y, range 30-92y); 69% with UICC/ FIGO stage III/IV cancer. 74.6% received Conmirnaty (BioNTech/ Pfizer), 18.9% Vaxzevria (AstraZeneca) and 6.5% Covid-19 Vaccine Moderna. After the first shot, 33.3% of the patients described no side effects, 49.1% reported a local reaction (swelling or pain), 23.4% flu-like symptoms, 10.8% headache and 3.6% nausea. 11 patients had symptoms that lasted longer than two days. In 11 cases, COVID-19 vaccination had an impact on delivery of the systemic therapy (n¼10 postponements of therapy and n¼1 dose reduction). 61.3% of the non-vaccinated patients (in total n¼118) were already registered to get vaccinated; 32.8% chose to postpone vaccination for personal reasons; 5% refused vaccination.

Conclusions: Breast and gynecological cancer patients appear to tolerate COVID-19 vaccination well under systemic therapy and only in few cases the vaccination interfered with the treatment schedule. Updated results will be presented at the ESMO Congress.

Legal entity responsible for the study: LMU University Hospital.

Funding: Has not received any funding. 

7%) and genitourinary (7%). 59% of the pts received chemotherapy,14.2% immunotherapy and 32.8% had radiotherapy over the past 12 months prior to receive the Covid 19 vaccination, which consisted of mRNA vaccines in 82.2% (Pfizer 46.2%, Moderna 36%). 4.9% of the pts refused vaccination. 82.3% of the pts had none (39.3%) or mild (43%) side-effects (S/E) and only 2.4% reported severe S/E. Most S/E lasted 1-3 days (89.4%) consisting mainly of sore arm (42.5%), headache (23.3%), fatigue (21.1%), and temperature (18.5%). Swollen lymph-nodes and allergic reactions were only reported in 0.7% (each). 49% of the pts were vaccinated while actively engaged on treatment, and in 96% there was no delay, interruption, or stoppage of the anticancer therapy. Conclusions: This is the first large report on Real word data voluntarily obtained from 1069 Belong.life users undergoing anticancer treatment with 90% of them receiving a Covid 19 vaccination. The large majority of pts had none or mild S/E (82.3%), and those were short lived (1-3 days in 89.4%) while only in 2% it was graded as severe

Consultant: MSD; Financial Interests, Personal, Advisory Role, Consultant: AstraZeneca. N. Moisa: Financial Interests, Personal, Full or part-time Employment: BelongTail. A. Litvin: Financial Interests, Personal, Full or part-time Employment: BelongTail. E. Malki: Financial Interests, Personal, Full or part-time Employment: BelongTail; Financial Interests, Personal, Full or part-time Employment: Belong.life. D.A. Vorobiof: Financial Interests, Personal, Full or part-time Employment: BelongTail; Financial Interests, Personal, Full or part-time Employment: Belong

1595P Acceptance of COVID-19 vaccination among cancer patients in an Irish cancer centre

Hospitalised cancer patients have a three times higher risk of death (14%) from COVID-19 than the general public. Vaccination provides an unprecedented opportunity to decrease morbidity & mortality, however, there is a limited data regarding cancer patients' attitudes towards COVID-19 vaccination. Methods: An anonymised questionnaire was completed by volunteering cancer patients attending the ambulatory care unit of a large tertiary cancer centre

Most (78%) had a good performance status (PS ¼ 0-1) & lung was the most frequent (28%) cancer type. Eight (6%) had previous COVID-19 infection. Among respondents, 128 (90%) intended on getting vaccinated, 12 (8%) were unsure & three (2%) would refuse. Those intent on vaccination were less concerned with side effects

Almost 20% (n¼28) reported that they were more likely to receive the flu vaccine due to the pandemic. Twelve (8%) identified attending their GP as a barrier, with 97% (n¼135) willing to attend hospital for vaccination. While this service is free, 69% (n¼99) were willing to pay